Literature DB >> 30262889

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Delphine Charvin1, Rossella Medori1, Robert A Hauser2, Olivier Rascol3.   

Abstract

Existing therapeutic strategies for managing Parkinson disease (PD), which focus on addressing the loss of dopamine and dopaminergic function linked with degeneration of dopaminergic neurons, are limited by side effects and lack of long-term efficacy. In recent decades, research into PD pathophysiology and pharmacology has focused on understanding and tackling the neurodegenerative processes and symptomology of PD. In this Review, we discuss the challenges associated with the development of novel therapies for PD, highlighting emerging agents that aim to target cell death, as well as new targets offering a symptomatic approach to managing features and progression of the disease.

Entities:  

Year:  2018        PMID: 30262889     DOI: 10.1038/nrd.2018.136

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  217 in total

1.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.

Authors:  Alexxai V Kravitz; Benjamin S Freeze; Philip R L Parker; Kenneth Kay; Myo T Thwin; Karl Deisseroth; Anatol C Kreitzer
Journal:  Nature       Date:  2010-07-07       Impact factor: 49.962

Review 2.  Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Authors:  Olivier Rascol; Susan Fox; Fabrizio Gasparini; Christopher Kenney; Thérèse Di Paolo; Baltazar Gomez-Mancilla
Journal:  Parkinsonism Relat Disord       Date:  2014-05-14       Impact factor: 4.891

3.  AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Authors:  Daniela Berg; Jana Godau; Claudia Trenkwalder; Karla Eggert; Iiona Csoti; Alexander Storch; Heiko Huber; Monica Morelli-Canelo; Maria Stamelou; Vincent Ries; Martin Wolz; Christine Schneider; Thérèse Di Paolo; Fabrizio Gasparini; Sam Hariry; Marc Vandemeulebroecke; Walid Abi-Saab; Katy Cooke; Donald Johns; Baltazar Gomez-Mancilla
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

5.  Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.

Authors:  Robert A Hauser; Kelly E Lyons; Terry McClain; Summer Carter; David Perlmutter
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

6.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

8.  The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study.

Authors:  K M Prakash; N V Nadkarni; W-K Lye; M-H Yong; E-K Tan
Journal:  Eur J Neurol       Date:  2016-01-25       Impact factor: 6.089

9.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

Review 10.  The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease.

Authors:  Erica L Gorenberg; Sreeganga S Chandra
Journal:  Front Neurosci       Date:  2017-05-19       Impact factor: 4.677

View more
  54 in total

Review 1.  Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration.

Authors:  Wesley Peng; Georgia Minakaki; Maria Nguyen; Dimitri Krainc
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 2.  Role of the endolysosomal system in Parkinson's disease.

Authors:  D J Vidyadhara; John E Lee; Sreeganga S Chandra
Journal:  J Neurochem       Date:  2019-07-31       Impact factor: 5.372

3.  Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?

Authors:  Ivan A Kuznetsov; Andrey V Kuznetsov
Journal:  Math Biosci       Date:  2021-12-07       Impact factor: 2.144

Review 4.  Closing the loop for patients with Parkinson disease: where are we?

Authors:  Hazhir Teymourian; Farshad Tehrani; Katherine Longardner; Kuldeep Mahato; Tatiana Podhajny; Jong-Min Moon; Yugender Goud Kotagiri; Juliane R Sempionatto; Irene Litvan; Joseph Wang
Journal:  Nat Rev Neurol       Date:  2022-06-09       Impact factor: 44.711

Review 5.  Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight.

Authors:  Priyanka Saklani; Heena Khan; Thakur Gurjeet Singh; Saurabh Gupta; Amarjot Kaur Grewal
Journal:  Mol Biol Rep       Date:  2022-06-03       Impact factor: 2.742

Review 6.  Progress, Opportunities, and Challenges of Magneto-Plasmonic Nanoparticles under Remote Magnetic and Light Stimulation for Brain-Tissue and Cellular Regeneration.

Authors:  Muzhaozi Yuan; Mackenzie Caitlin Harnett; Tian-Hao Yan; Elias Georgas; Yi-Xian Qin; Hong-Cai Zhou; Ya Wang
Journal:  Nanomaterials (Basel)       Date:  2022-06-29       Impact factor: 5.719

7.  Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.

Authors:  Tsu-Kung Lin; Kai-Jung Lin; Hung-Yu Lin; Kai-Lieh Lin; Min-Yu Lan; Pei-Wen Wang; Tzu-Jou Wang; Feng-Sheng Wang; Po-Chin Tsai; Chia-Wei Liou; Jiin-Haur Chuang
Journal:  Front Mol Neurosci       Date:  2021-07-07       Impact factor: 5.639

8.  Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinson's Disease.

Authors:  Osmar Vieira Ramires Júnior; Barbara da Silva Alves; Paula Alice Bezerra Barros; Jamile Lima Rodrigues; Shana Pires Ferreira; Linda Karolynne Seregni Monteiro; Gabriela de Moraes Soares Araújo; Sara Silva Fernandes; Gustavo Richter Vaz; Cristiana Lima Dora; Mariana Appel Hort
Journal:  Neurotox Res       Date:  2021-04-16       Impact factor: 3.978

Review 9.  The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease.

Authors:  Jiang-Fan Chen; Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2020-03-31       Impact factor: 3.765

Review 10.  Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.

Authors:  Priscila Baltazar Gonçalves; Ana Carolina Rennó Sodero; Yraima Cordeiro
Journal:  Biomolecules       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.